Keywords: پسوریازیس; Psoriasis; Ovarian reserve; Psoriatic area severity index; Antral follicular count; Follicle-stimulating hormone;
مقالات ISI پسوریازیس (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: پسوریازیس; Psoriasis; Childhood trauma; Resilience; Quality of life; Psychological distress; Psychosomatic;
Keywords: پسوریازیس; dose escalation; dose optimization; psoriasis; secukinumab; AE; adverse event; PASI; Psoriasis Area and Severity Index; PASI-75; 75% reduction from baseline PASI score; PGA; Physician Global Assessment;
Keywords: پسوریازیس; Mantoux test; protein purified derivative test; psoriasis; reverse Koebner phenomenon; KP; Koebner phenomenon;
Keywords: پسوریازیس; alopecia areata; psoriasis; Renbök phenomenon; trichoscopy; AA; alopecia areata; CI; confidence interval; IL; interleukin; OR; odds ratio; PsA; psoriatic arthritis; Th; T helper; TNF; tumor necrosis factor;
Keywords: پسوریازیس; Anxiety; Psoriasis; Self-esteem; Coping; Coping strategies;
Keywords: پسوریازیس; hyperpigmentation; lentigines; macules; plaque; psoriasis; ELRP; eruptive lentiginosis in resolving psoriatic plaques; IL; interleukin; TNF; tumor necrosis factor;
Keywords: پسوریازیس; Biologics; enteropathic arthritis; HLA-B27; MRCP; psoriasis; psoriatic arthritis; sacroiliitis; spondylitis;
Keywords: پسوریازیس; Balanitis; Candida; eczema; erythrasma; genital warts; lichen sclerosus; MRCP; pediculosis pubis; psoriasis; scabies; tinea cruris; vulvitis;
Keywords: پسوریازیس; biologic; cardiovascular; mortality; myocardial infarction; psoriasis; stroke; TNF inhibitor;
Keywords: پسوریازیس; Drug survival; Effectiveness; Biologic therapy; Psoriasis; Risk factors;
Keywords: پسوریازیس; Psoriasis; Artritis psoriásica; Enfermedades cutáneas papuloescamosas; Fotoquimioterapia; Anticuerpos monoclonales; Psoriasis; Psoriatic arthritis; Papulosquamous skin disorders; Photochemotherapy; Monoclonal antibodies;
Keywords: پسوریازیس; Psoriasis; Cognitive impairment; Anxiety; Depression; Quality of life;
Keywords: پسوریازیس; Psoriasis; Keratinocyte; Biological agents; Phosphodiesterase-4(PDE4) inhibitors; Janus kinases inhibitors; microRNA;
Keywords: پسوریازیس; Ang II; angiotensin II; BSA; bovine serum albumin; INF; interferon; IL; interleukin; MPO; myeloperoxidase; NAG; N-acetyl-β-D-glucosaminidase; PCNA; proliferating cell nuclear antigen; RAS; renin-angiotensin System; TNF; tumor necrosis factor; Psoriasis;
Keywords: پسوریازیس; Cryptococcus neoformans; Primary cutaneous cryptococcosis; Cryptococcemia; Psoriasis; Tinea; Nephrotic syndrome; Focal segmental glomerulosclerosis; Misdiagnosis;
Keywords: پسوریازیس; insomnia; obstructive sleep apnea; pain; pruritus; psoriasis; sleep deficiency; sleep habits;
Keywords: پسوریازیس; Inflammatory bone loss; Arthritis; Colitis; Psoriasis; Peripheral quantitative computed tomography;
Keywords: پسوریازیس; 4PL; 4 parameters logistic regression; DEGs; Differentially expressed genes; ELISA; Enzyme-linked immunosorbent assays; FC; Fold change; GEO; Gene Expression Omnibus; LC/GC-MS; Liquid chromatography/Gas chromatography-mass spectrometry; PASI; Psoriasi
Keywords: پسوریازیس; Psoriasis; Keratinocyte; Gene expression; Epigenetics; Bioinformatics;
Keywords: پسوریازیس; fixed combination; halobetasol; psoriasis; tazarotene; topical; AE; adverse event; BSA; body surface area; DLQI; Dermatology Life Quality Index; HP/TAZ; halobetasol propionate 0.01% plus tazarotene 0.045%; IGA; Investigator's Global Assessment; QoL; quali
Keywords: پسوریازیس; administrative databases; diagnosis; psoriasis; psoriatic arthritis;
Keywords: پسوریازیس; adalimumab; etanercept; indirect comparison; psoriasis;
Keywords: پسوریازیس; Psoriasis; Epidemiology; Comorbidity; Biologics; Interleukin-17a inhibitor; Interleukin-23 inhibitor;
Keywords: پسوریازیس; Psoriasis; Erectile Dysfunction; Sexual Dysfunction; Meta-Analysis;
Keywords: پسوریازیس; Psoriasis; Proteome; 4-HNE-protein adducts; Plasma;
Keywords: پسوریازیس; Psoriasis; Systematic reviews; Methodological quality; AMSTAR; PRISMA for abstract; Abstract readability; Altmetrics;
Keywords: پسوریازیس; Skin delivery; Microemulsion; Psoriasis; Thickening; Cyclosporine; Polysorbate 80; Tween®80; Vitamin E TPGS; Viscosity;
Keywords: پسوریازیس; Chronic pruritus; Chronic itch; Atopic dermatitis; Psoriasis; Uremic pruritus; Cholestatic pruritus; Novel therapies;
Keywords: پسوریازیس; S1PR1; Soft-drug; Plasma stability; Psoriasis; Topical;
Keywords: پسوریازیس; AD; atopic dermatitis; CGRP; calcitonin gene-related peptide; DRG; dorsal root ganglion; GR; glucocorticoid receptor resistance; HPA; hypothalamus-pituitary-adrenal; NGF; nerve growth factor; PACAP; pituitary adenylate cyclase-activating polypeptide; SP;
Keywords: پسوریازیس; Dermoscopy; Inflammatory genital diseases; Lichen sclerosus; Lichen planus; Psoriasis; Eczema; Plasma cell mucositis;
Keywords: پسوریازیس; Psoriasis; Pathogenesis; Keratinocyte; Galectin-3; Neutrophil;
Keywords: پسوریازیس; Skin disorders; suicide; psoriasis; acne; dermatitis;
Keywords: پسوریازیس; Psoriasis; Tratamiento; Agentes biológicos; Encuesta; Dermatólogos; Psoriasis; Treatment; Biologic agents; Survey; Dermatologists;
Keywords: پسوریازیس; adverse events; depression; mental health; psoriasis; psychiatric; psychiatry; suicidal ideation and behavior; AE; adverse event; C-SSRS; Columbia Suicide Severity Rating Scale; eC-SSRS; electronic Columbia Suicide Severity Rating Scale; HADS; Hospital An
Keywords: پسوریازیس; Psoriasis; Nanocarriers; Delivery systems; Patents; Pathogenesis;
Keywords: پسوریازیس; Intermittent hypoxia; Chronic inflammation; Obstructive sleep apnea; Systemic lupus erythematosus; Rheumatoid arthritis; Psoriasis; Neuro-inflammation; Raynaud's phenomenon; Sleep deprivation; Obesity;
Keywords: پسوریازیس; aHR; adjusted hazard ratio; BMI; body mass index; CI; confidence interval; GP; general practitioner; HR; hazard ratio; iHOPE; Incident Health Outcomes and Psoriasis Event; NAFLD; nonalcoholic fatty liver disease; PsA; psoriatic arthritis; PsO; psoriasis;
Keywords: پسوریازیس; AD; atopic dermatitis; CCL; chemokine (C-C motif) ligand; CXCL; chemokine (C-X-C motif) ligand; CXCR; chemokine (C-X-C motif) receptor; DEG; differentially expressed gene; FC; fold changes; KLK; kallikrein; MRGPR; Mas-related G-protein coupled receptor; N
Keywords: پسوریازیس; AIKD; autoinflammatory keratinization diseases; CAPS; cryopyrin-associated periodic syndrome; CARD14; caspase recruitment domain family member 14; FMF; familial Mediterranean fever; GPP; generalized pustular psoriasis; IL-36Ra; IL-36 receptor antagonist;
Keywords: پسوریازیس; Nail; Psoriasis; Onychomycosis; Porosity; Ciclopirox; Clobetasol propionate;
Keywords: پسوریازیس; Psoriasis; Vitamin D3-containing ointment; Calcemic effect; Systemic exposure; Vitamin D receptor target gene; Skin atrophy;
Keywords: پسوریازیس; Inflammation; Psoriasis; Autoimmune; Hypertension;
Keywords: پسوریازیس; 4 years; interleukin 17; ixekizumab; long-term; open-label; psoriasis; BCC; basal cell carcinoma; DLQI; Dermatology Life Quality Index; HADS; Hospital Anxiety and Depression Scale; IBD; inflammatory bowel disease; IL; interleukin; LOCF; last observation c
Keywords: پسوریازیس; Inflammation; Psoriasis; Resolution; Lipid mediators; Essential polyunsaturated fatty acids; DHA;
Keywords: پسوریازیس; Itch; Pruritus; Anxiety; Stress; Amygdala; Atopic dermatitis; Psoriasis;
Keywords: پسوریازیس; Methotrexate; Chitin nanogel; Anti-inflammatory; Immuno suppressant; Psoriasis;
Keywords: پسوریازیس; PASI; Psoriasis Area and Severity Index; IL; interleukin; fzd; frizzled receptors; IFN; interferon; ADAM; a disintegrin and metalloproteinase; EGF; epidermal growth factor; TGF; transforming growth factor; TPA; 12-o-tetradecanoyl phorbol-13-acetate; VEGF;
Keywords: پسوریازیس; Psoriasis; Angiogenesis; Inflammation; Cannabinoids; JWH-133;